Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 4;7(1):178.
doi: 10.1038/s41392-022-01040-9.

Low-dose metformin and PEN2-dependent lysosomal AMPK activation: benefits outnumber side effects

Longlong Liu  1 , Pradeep Kumar Patnana  1 , Subbaiah Chary Nimmagadda  2
Affiliations
Comment

Low-dose metformin and PEN2-dependent lysosomal AMPK activation: benefits outnumber side effects

Longlong Liu et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematic illustration of low- and high-dose metformin-induced signalling events leading to AMPK activation. a (green): Low-dose metformin-PEN2 and low-glucose sensor, aldolase signalling intersect at v-ATPase and results in AMPK activation. This is associated with postprandial glucose reduction, hepatic fat reduction, and life span extension. b (red): High-dose metformin activates AMPK signalling independent of the PEN2-ATP6AP1 axis and triggers a spectrum of other pathways. AMP adenosine monophosphate, ATP adenosine triphosphate, AMPK AMP-activated protein kinase, ATP6AP1 accessory factor of v-ATPase, ETC electron transport chain, LKB1 liver kinase B1, OCT organic cation transporters, PEN2 presenilin enhancer 2. The figure was created with a paid license on BioRender.com
See this image and copyright information in PMC

Comment on

  • Low-dose metformin targets the lysosomal AMPK pathway through PEN2.
    Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, Wu J, Wei X, Qu Q, Yu Y, Long S, Feng JW, Li C, Zhang C, Xie C, Wu Y, Xu Z, Chen J, Yu Y, Huang X, He Y, Yao L, Zhang L, Zhu M, Wang W, Wang ZC, Zhang M, Bao Y, Jia W, Lin SY, Ye Z, Piao HL, Deng X, Zhang CS, Lin SC. Ma T, et al. Nature. 2022 Mar;603(7899):159-165. doi: 10.1038/s41586-022-04431-8. Epub 2022 Feb 23. Nature. 2022. PMID: 35197629 Free PMC article.

References

    1. Ma T, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. 2022;603:159–165. doi: 10.1038/s41586-022-04431-8. - DOI - PMC - PubMed
    1. Zhang CS, et al. Metformin activates AMPK through the lysosomal pathway. Cell Metab. 2016;24:521–522. doi: 10.1016/j.cmet.2016.09.003. - DOI - PubMed
    1. Liu, L. et al. High metabolic dependence on oxidative phosphorylation drives sensitivity to metformin treatment in MLL/AF9 acute myeloid leukemia. Cancers14, 486 (2022). - PMC - PubMed
    1. Podhorecka M. Metformin—its anti-cancer effects in hematologic malignancies. Oncol. Rev. 2021;15:514. doi: 10.4081/oncol.2021.514. - DOI - PMC - PubMed
    1. Mohammed I, Hollenberg MD, Ding H, Triggle CR. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front. Endocrinol. 2021;12:718942. doi: 10.3389/fendo.2021.718942. - DOI - PMC - PubMed

Publication types

MeSH terms